Lupin launches fenofibrate in the US

The drug helps in managing cholesterol

Lupin has announced the launch of the authorised generic version of Antara (Fenofibrate) capsules, 30 mg and 90 mg, of Lupin Atlantis Holdings, S.A. Corporation, a wholly-owned subsidiary of Lupin.

Fenofibrate capsules are indicated as adjunctive therapy to diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (total-c), Triglycerides rrG) and apolopoprotein B (Apo B), and to increase high-density fipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia.

Fenofibrate Capsules (RLD: Antara capsules) had estimated annual sales of US $ 7 million in the U.S. (IQVIA MAT September 2021).